Intravascular large B-cell lymphoma (ILBCL) is a rare and aggressive extranodal lymphoma characterized by the proliferation of large CD20+ lymphoma cells almost exclusively within the lumina of small and intermediate vessels. Widespread extranodal involvement is common and may involve almost any organ, leading to protean and often nonspecific clinical manifestations.
Intravascular large B-cell lymphoma (ILBCL) is a rare and aggressive extranodal lymphoma characterized by the proliferation of large CD20+ lymphoma cells almost exclusively within the lumina of small and intermediate vessels. Widespread extranodal involvement is common and may involve almost any organ, leading to protean and often nonspecific clinical manifestations. 1 Given the broad spectrum of clinical presentations and the intravascular nature of the disease process, which generally progresses without the development of lymphadenopathy or a discrete radiographically identifiable mass, the diagnosis of ILBCL can be particularly elusive. Indeed, historically, ILBCL has predominantly been a diagnosis made at the time of autopsy. 2 Due to frequent bone marrow infiltration, 3 cytopenias often develop, 4, 5 for which a bone marrow biopsy is obtained. However, due to the exclusive intrasinuisoidal involvement of ILBCL in what is often an otherwise unremarkable marrow, detection on H&E alone represents a substantial diagnostic challenge. The role of routine cytogenetics in the diagnosis of an occult ILBCL has yet to be investigated.
While ILBCL has been associated with complex karyotypes in various case reports and small series, aggregated data characterizing its cytogenetic landscape are limited. In this study, we developed a comprehensive karyotypic data set comprising all previously published reports as well as several novel cases and analyzed it for the presence of recurrent cytogenetic abnormalities.
Materials and Methods
With approval from the University of Tennessee Health Science Center Institutional Review Board, an institutional database was searched for all surgical specimens and bone marrow biopsy specimens with a diagnosis of ILBCL between 2007 and 2017. All identified cases were independently reviewed to confirm the diagnosis of ILBCL according to 2008 World Health Organization criteria. 6 Patient demographics and clinical history were recorded. Conventional cytogenetic analysis had been performed on all four bone marrow specimens at the time of diagnosis.
A literature search using PubMed was subsequently conducted to identify all previously published cases of ILBCL with complete karyotypic data. The following search terms were used: intravascular large B-cell lymphoma, intravascular lymphoma, intravascular lymphomatosis, and angiotropic large cell lymphoma. The search limits "humans" and "English language" were applied.
The karyotypic data of newly identified institutional cases and previously published cases were pooled and systematically parsed according to locus-specific aberrations ❚Table 1❚, ❚Figure 1❚, and ❚Figure 2❚.
Results
Four institutional cases of ILBCL were identified, all of which had bone marrow biopsy specimens and one of which had a preceding brain biopsy specimen. Conventional cytogenetics had been performed on the bone marrow aspirates of all four cases at the time of diagnosis, and all showed complex karyotypes. Each case is described in detail below.
Case 1
Patient 1 was a 48-year-old African American man who sought treatment from the emergency department (ED) with a 1-week history of progressive left hemiparesis. He had recently been diagnosed with adenocarcinoma of unknown primary origin metastatic to the adrenal gland. Complete metabolic panel was within normal limits. CBC was remarkable only for leukocytosis (13.5 × 10 9 /L). A computed tomography (CT) scan of the abdomen and pelvis demonstrated bilateral adrenal enlargement and mild splenomegaly. Magnetic resonance imaging (MRI) of the brain revealed an acute infarction involving the cerebellum, left occipital lobe, and parietooccipital lobes bilaterally. A brain biopsy was performed and showed intravascular B-cell lymphoma. A subsequent bone marrow biopsy specimen was obtained, which confirmed the diagnosis of ILBCL. Flow cytometry performed on the bone marrow aspirate showed a small subpopulation (0.7% of total events) of CD20+ cells with high forward scatter and a κ/λ ratio of 7.2. Conventional cytogenetic analysis revealed a complex karyotype: 45,X,-Y,dup(1)(q22q44),?t(3;9)(q26; p24),t(8;8)(q22;q24), der(11)t(1;11)(q21;p15), del(12) (p13),add(17)(q25) [15] /46,XY [7] . Treatment with rituximab was initiated, but he subsequently developed multiorgan failure and died. [15] . She was treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and remains alive 7 years postdiagnosis.
Case 3
The patient was a 71-year-old white man with a history of type 2 diabetes mellitus, hypertension, chronic kidney disease, coronary artery disease, atrial fibrillation, and obstructive sleep apnea who sought treatment from the ED for fever and weakness. Laboratory evaluation revealed pancytopenia (WBC count, 2.9 × 10 9 /L; hemoglobin, 9.0 g/dL; platelet count, 72 × 10 9 /L). CT scans of the chest, abdomen, and pelvis were remarkable for mild splenomegaly. A bone marrow biopsy was performed and revealed ILBCL. Flow cytometry performed on the bone marrow aspirate did not identify a monoclonal B-cell population. Conventional cytogenetic analysis revealed a complex karyotype: 81, XXYY, del(6) (q13), t(7;11)(q32;q14)x2,t(8;22)(q12;q11.2), add(19) (q13.4)x2 [8] /46, XY [12] . Treatment was initiated at an outside hospital, and follow-up data were not available.
Case 4
Patient 4 was a 69-year-old African American woman with a history of hypertension and hyperlipidemia who went to the ED following a syncopal episode. She was (7) (p11), +add(7)(q11), add(9)(p24), der(9)t(9;11)(p13;q11), +add(12)(p11), der(14)(q32;q15), -15, add (15) 79-83,XY,add(X)(p11),-Y,-1,add(1)(p36)x2,-4,add(4)(q35),-6,-6,add(7)(q31)x2, +add(7)(q22),-8,add(8)(p11),i(8) (q10)x2,-9,add(9)(p23)x2,del(9)(p13),-10, -10, add (10) 40-48,XX,+X,der(1)t(1;11)(p13;q11),der(1)t(1;14)(p13;q32)add(14)(q32), add(2)(q37), der(4)add(4)(p15.2)t(4;6) (q21;p23), der(6)t(4;6), add(9)(p22), del(11)(q13q25), add(14)(q32), der (14) /L). LDH was elevated (>5,700 U/L). International normalized ratio (2.5) and activated partial thromboplastin time (aPTT) (45 seconds) were persistently elevated; mixing studies ruled out the presence of an inhibitor, and factor II, V, VII, VIII, and X and lupus anticoagulant assays were normal. CT scan of the head and MRI/magnetic resonance angiography were unremarkable. CT scans of the chest, abdomen, and pelvis revealed granulomatous calcification in the left hilum and right lower lobe of the lung and multiple hepatic cysts. Electroencephalogram was consistent with generalized encephalopathy. Upon review of the patient's peripheral blood smear, dacrocytes and nucleated RBCs were evident. A bone marrow biopsy was subsequently performed and revealed ILBCL ❚Image 2❚. Flow cytometry performed on the bone marrow aspirate did not reveal the presence of a monoclonal B-cell population. Conventional cytogenetic analysis revealed a complex karyotype: 49,XX,+5,-6,del(7)(q22q32),?t(13;22) (p11.2;q11.2), add(15)(q26), add(16)(q24),+18,+21,+mar [6] . The patient declined treatment for religious reasons.
From the literature, 25 cases of ILBCL with complete karyotypic data were identified (results summarized in Table 1 and Figures 1 and 2) . In total, 21 (72.4%) of 29 patients had abnormalities involving chromosome 1. Ten translocations were present in eight patients, of whom six had either p13 or q21. In total, nine (31.0%) of 29 patients had 11 rearrangements involving 1p13 or 1q21. Seventeen (58.6%) of 29 patients had abnormalities involving chromosome 3. The most common rearrangement was a translocation, which was definitively present in eight patients, of whom three had 3p21. Seventeen (58.6%) of 29 patients had abnormalities involving chromosome 6. In almost all cases, the long arm of chromosome 6 was implicated, including eight patients with additional material of unknown origin and five 6q deletions. Twelve (41.4%) patients had abnormalities involving chromosome 14, 10 (34.5% of total) of whom had rearrangements of 14q32. Sixteen (55.2%) patients had abnormalities of chromosome 18. Eleven (37.9%) of 29 total patients had trisomy 18. At least one marker chromosome was present in 14 (48.3%) of 29 patients.
❚Image 1❚ Bone marrow biopsy from patient 2 demonstrating involvement by intravascular large B-cell lymphoma (ILBCL). A, The detection of ILBCL in the bone marrow on H&E alone can be particularly challenging as the lymphoma cells are distributed in a subtle, sinuisoidal pattern and tend to blend seamlessly with the other hematopoietic elements (x200). B, CD20 immunostain clearly highlights the extensive intrasinuisoidal infiltration of large, atypical B lymphocytes (x200).
❚Image 2❚ Bone marrow biopsy from patient 4 demonstrating involvement by intravascular large B-cell lymphoma (ILBCL). A, Infiltration of a sinusoid by large, atypical lymphocytes is appreciable even on H&E in this example (×400). B, CD20 immunostain shows the exclusive intrasinuisoidal distribution of the large lymphoma cells (×400).
The results of this study, which represents the largest combined karyotypic data set currently published, demonstrate that recurrent cytogenetic abnormalities involving chromosomes 1, 6q, and 18 are present in greater than 50% of ILBCLs. All cases uniformly exhibited complex karyotypes (three or more aberrations), with a median of 10 aberrations. In 48.3% of patients, at least one marker chromosome was present.
Structural abnormalities in chromosome 1 represent the most common category of recurrent aberrations present in patients with ILBCL (72.4%). Two loci in particular-1p13 and 1q21-were implicated in nine (31.0%) of 29 patients. While the involved content of the 1p13 band remains unclear, it is interesting that part of this region contains the NOTCH2 gene, which encodes a transmembrane receptor implicated in mature B-lymphocyte development and, when dysregulated, lymphomagenesis with an aggressive clinical course. [23] [24] [25] [26] [27] [28] [29] Mutations of NOTCH2 have been identified in up to 25% of splenic marginal zone lymphomas and have been associated with reduced treatment-free survival and a poor prognosis. [25] [26] [27] Among nodal marginal zone lymphomas, NOTCH2 mutations have been reported in 20%. 28 Mutations of NOTCH2 have also been reported in up to 8% of diffuse large B-cell lymphomas (DLBCLs) 24 and in 20% of patients with DLBCL with hepatitis C virus infection, among whom they were associated with decreased overall survival. 29 Another interesting candidate gene that resides on the 1p13 band is CD58, which encodes a cell surface protein involved in T-cell and natural killer (NK)-cell adhesion and activation. The loss or inactivation of CD58 in DLBCL has been associated with a poor prognosis, possibly by enabling evasion of immune surveillance. 30, 31 The presence of NOTCH2 and CD58 mutations in ILBCL and their associated prognostic impact remains an area for future investigation.
The 1q21 breakpoint is frequently involved in DLBCL, most commonly as a translocation partner, which was also the case with ILBCLs in this study. In a series of 215 DLBCLs with cytogenetic abnormalities, 1q21 rearrangements were present in 36% of cases, representing the third most common breakpoint. 32 Dysregulation of multiple genes that reside on the 1q21 band have been reported in a variety of B-cell lymphomas, including MUC1, 33, 34 
BCL9,
35 IRTA1/2, 36 and FCGR2B. 37 However, the prognostic impact of 1q21 rearrangements in DLBCL is not entirely clear. While in one large series 1q21 rearrangements were associated with decreased overall survival, 38 a later study found a similar correlation on univariate but not multivariate analysis when controlled for age, stage, performance status, and LDH level. 39 Interestingly, in multiple myeloma, amplification of 1q21 has been identified as a poor prognostic marker [40] [41] [42] owing to the overexpression CKS1B, which promotes cell cycle progression by participating in the ubiquitination and degradation of p27, a cell cycle inhibitor. 43 The potential role of CKS1B dysregulation in ILBCL has not yet been investigated.
In total, 58.6% of patients demonstrated an abnormality of chromosome 6, and in 83.3% of these patients, an aberration involving 6q was present. While eight of these patients had additional material of unknown origin and five had 6q deletions, it should be noted that additional material can be associated with deletions in the corresponding region; thus, the incidence of 6q deletions may in fact be higher. In four (13.8%) cases, the 6q21-q23 region was involved, and in four (13.8%) other cases, there was loss of 6. Interestingly, the 6q21-q22 region carries the tumor suppressor gene PRDM1, 44, 45 which has been shown to be deleted in 24% to 25% of activated B-cell-like (ABC) DLBCLs and epigenetically inactivated in an additional ~50% of ABC-DLBCLs. 46, 47 Loss of PRDM1 function in patients with ABC-DLBCL has been associated with a poor prognosis. 48 PRDM1 has also been shown to be frequently inactivated in anaplastic large cell lymphoma 49 and NK-cell lymphoma.
50,51
Rearrangements of 11q13 were present in six (20.7%) patients. While t(11;14)(q13;q32), resulting in cyclin D1 overexpression, is a hallmark of mantle cell lymphoma, the role of 11q13 rearrangements in the pathogenesis of other lymphomas, and whether the cyclin D1 locus is implicated in ILBCL specifically, remains unclear. Yoshioka et al 52 reported a high incidence of 11q13 rearrangements in de novo CD5+ DLBCL. In one study, gain of 11q11-q13 using comparative genomic hybridization (CGH) was identified in 42% of salivary gland mucosaassociated lymphoid tissue (MALT) lymphomas. 53 Using CGH, recurrent gains of 11q13 have also been reported in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma not otherwise specified. 54 The immunoglobulin H locus, 14q32, was rearranged in 10 (34.5%) patients and involved as a translocation partner in seven (24.1% of total) patients. A similar phenomenon has been documented in DLBCL, where 14q32 rearrangements account for the most common cytogenetic abnormality. 32 Among patients with DLBCL, Cigudosa et al 32 reported that translocations involving 14q32 represented 51% of all chromosomal aberrations. However, the most common 14q32 translocation partners among DLBCL cases were 18q21 (BCL2 locus), 8q24 (MYC locus), and 3q27 (BCL6 locus), none of which were identified in this study.
Trisomy 18, present in 37.9% of patients in this study, has been reported in both high-grade and low-grade lymphomas. In one series of 192 bone marrow specimens involved by DLBCL with cytogenetic abnormalities, trisomy 18 was the most common numerical abnormality, present in 32 (21.3%) of 150 patients with chromosomal aberrations except those with single numerical aberrations. 55 However, no statistically significant correlation with prognosis was observed. In a study of patients with non-MALT marginal zone lymphomas, which included 44 patients with cytogenetic abnormalities, 14 (31.8%) patients had abnormalities involving chromosome 18. 56 Dierlamm et al 57 reported the frequency of trisomy 18 in marginal zone lymphomas to be 39.1% among those with cytogenetic abnormalities and 29.0% overall. Among patients with MALT lymphomas, the frequency of trisomy 18 has been reported to be approximately 20%. 58 Among all B-cell lymphomas harboring trisomy 18, no clear prognostic significance or role in pathogenicity has been identified.
It is important to note that all but two karyotypes were obtained from bone marrow aspirates, highlighting the amenability of ILBCL to routine cytogenetic analysis. In contrast, a clonal B-cell population could only be identified by flow cytometry in two of the four cases identified from our institutional database, which was confirmed upon retrospective review. The reason for this discrepancy is not entirely clear. Historically, the sensitivity of flow cytometric detection of large cell lymphomas has been reported to be as low as 75%. 59 A larger sample size would be required to determine the true sensitivity of flow cytometry for the detection of ILBCL. However, possible explanations for the low sensitivity observed in this study potentially include increased fragility of the tumor cells and loss of viability during processing and/or low tumor cellularity of the sample owing to lack of uniform marrow involvement and suboptimal sample size. 59 The observation that ILBCL is uniformly associated with complex karyotypes and multiple recurrent cytogenetic abnormalities may be of use in alerting the pathologist to the possible presence of an occult ILBCL in a seemingly morphologically unremarkable bone marrow biopsy specimen. Indeed, whereas aggregates of the large atypical lymphocytes characteristic of ILBCL may be readily identified within the lumina of small vessels in the viscera and skin on H&E alone, their recognition in the bone marrow sinusoids, where they can blend seamlessly with other hematopoietic elements, represents a formidable diagnostic challenge. In the absence of routine CD20 staining, it not unlikely that a number of cases go either undiagnosed or misdiagnosed. For example, it is not inconceivable that a case of ILBCL that has cytopenia(s), a complex karyotype, and subtle dysplasia might be mislabeled as a myelodysplastic syndrome (ie, myelodysplastic syndrome, unclassifiable). Based on the results of this study, it would be prudent to consider intravascular large B-cell lymphoma in the differential diagnosis of a seemingly unremarkable bone marrow with a complex karyotype involving aberrations of chromosomes 1, 6q, and 18, the first step in the workup of which is an immunohistochemical stain for CD20.
In summary, the results of this study demonstrate that ILBCL is consistently associated with a complex karyotype and multiple recurrent cytogenetic abnormalities, the recognition of which may facilitate the diagnosis of this elusive disease. Further investigation is warranted to delineate the specific genetic events underlying these aberrations and their prognostic significance.
